Product
Pramlintide
Aliases
Symlin
5 clinical trials
9 indications
Indication
Type 1 DiabetesIndication
HypoglycemiaIndication
Previous Gastric SurgeryIndication
Cutaneous Squamous Cell CarcinomaIndication
Alzheimer's diseaseIndication
Mild Cognitive ImpairmentIndication
Diabetes MellitusIndication
Type 1Indication
Postprandial HyperglycemiaClinical trial
A Randomized, Controlled, Crossover Pilot Trial to Assess a Fully Automated, Dual-hormone (Insulin-and-pramlintide) Artificial Pancreas Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 DiabetesStatus: Completed, Estimated PCD: 2023-03-25
Clinical trial
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass SurgeryStatus: Completed, Estimated PCD: 2016-07-01
Clinical trial
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot StudyStatus: Withdrawn, Estimated PCD: 2023-06-26
Clinical trial
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System to Regulate Glucose Levels in Adults Living With Type 1 Diabetes: a Randomized, Controlled, Crossover Trial.Status: Recruiting, Estimated PCD: 2024-04-01